110 related articles for article (PubMed ID: 21345303)
1. Ineffectiveness of tumor necrosis factor-alpha inhibition in association with bisphosphonates for the treatment of cherubism.
Pagnini I; Simonini G; Mortilla M; Giani T; Pascoli L; Cimaz R
Clin Exp Rheumatol; 2011; 29(1):147. PubMed ID: 21345303
[No Abstract] [Full Text] [Related]
2. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
[TBL] [Abstract][Full Text] [Related]
3. Cherubism treated with calcitonin: report of a case.
de Lange J; van den Akker HP; Scholtemeijer M
J Oral Maxillofac Surg; 2007 Aug; 65(8):1665-7. PubMed ID: 17656300
[No Abstract] [Full Text] [Related]
4. Does anti-TNF-alpha have a role in the treatment of osteoporosis?
McMahon MS; Ueki Y
Bull NYU Hosp Jt Dis; 2008; 66(4):280-1. PubMed ID: 19093904
[No Abstract] [Full Text] [Related]
5. Denosumab in postmenopausal women with low bone mineral density.
Rifkin WD
N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010
[No Abstract] [Full Text] [Related]
6. Radiologically significant joint improvement in a patient affected by psoriatic arthritis treated with adalimumab.
Chimenti MS; Papoutsaki M; Teoli M; Zangrilli A; Perricone R; Chimenti S
Clin Exp Rheumatol; 2009; 27(6):1056. PubMed ID: 20149332
[No Abstract] [Full Text] [Related]
7. Successful treatment of recalcitrant genital ulcers of Behçet's disease with adalimumab after failure of infliximab and etanercept.
Olivieri I; D' Angelo S; Padula A; Leccese P; Mennillo GA
Clin Exp Rheumatol; 2009; 27(2 Suppl 53):S112. PubMed ID: 19796550
[No Abstract] [Full Text] [Related]
8. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.
Leccese P; D'Angelo S; Angela P; Coniglio G; Olivieri I
Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S102. PubMed ID: 20868587
[No Abstract] [Full Text] [Related]
9. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab.
Cohen JD; Ferreira R; Jorgensen C
J Rheumatol; 2011 Jul; 38(7):1527. PubMed ID: 21724733
[No Abstract] [Full Text] [Related]
10. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab in juvenile rheumatoid arthritis.
de Vries MK; van der Horst-Bruinsma IE; Wolbink GJ
N Engl J Med; 2008 Dec; 359(23):2496; author reply 2496-7. PubMed ID: 19065700
[No Abstract] [Full Text] [Related]
12. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report.
Benucci M; Li GF; Del Rosso A; Manfredi M
Clin Exp Rheumatol; 2005; 23(5):733. PubMed ID: 16173267
[No Abstract] [Full Text] [Related]
14. Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
Barthel HR; Gille T; Halbsguth A; Kramer M
J Gastroenterol Hepatol; 2005 Sep; 20(9):1464-5. PubMed ID: 16105142
[No Abstract] [Full Text] [Related]
15. Denosumab for postmenopausal osteoporosis?
Drug Ther Bull; 2012 Jan; 50(1):6-8. PubMed ID: 22241889
[TBL] [Abstract][Full Text] [Related]
16. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
17. Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab.
Sitapati AM; Kao CL; Cachay ER; Masoumi H; Wallis RS; Mathews WC
Clin Infect Dis; 2010 Jan; 50(2):e7-10. PubMed ID: 20001539
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
[TBL] [Abstract][Full Text] [Related]
19. Development of type 1 diabetes mellitus in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor alpha.
Richez C; Blanco P; Gin H; Schaeverbeke T
Clin Exp Rheumatol; 2006; 24(5):607. PubMed ID: 17181936
[No Abstract] [Full Text] [Related]
20. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
González-Gay MA; Agudo M
Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
[No Abstract] [Full Text] [Related]
[Next] [New Search]
